Insider Transactions in Q1 2022 at Dexcom Inc (DXCM)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 29
2022
|
Barry J. Regan EVP Operations |
SELL
Open market or private sale
|
Direct |
1,106
-6.34%
|
$553,000
$500.0 P/Share
|
|
Mar 23
2022
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
250
-0.7%
|
$114,750
$459.98 P/Share
|
|
Mar 17
2022
|
Matthew Vincent Dolan EVP Strategy and Corporate Dev |
SELL
Open market or private sale
|
Direct |
484
-6.8%
|
$217,800
$450.0 P/Share
|
|
Mar 16
2022
|
Matthew Vincent Dolan EVP Strategy and Corporate Dev |
SELL
Open market or private sale
|
Direct |
686
-8.79%
|
$291,550
$425.0 P/Share
|
|
Mar 15
2022
|
Kevin R Sayer President CEO and Chairman |
SELL
Open market or private sale
|
Direct |
3,000
-0.3%
|
$1,230,000
$410.78 P/Share
|
|
Mar 15
2022
|
Matthew Vincent Dolan EVP Strategy and Corporate Dev |
SELL
Open market or private sale
|
Direct |
1,016
-11.52%
|
$418,592
$412.41 P/Share
|
|
Mar 10
2022
|
Shelly Ramasamy Selvaraj SVP Chief Information Officer |
SELL
Open market or private sale
|
Direct |
2,366
-17.12%
|
$948,766
$401.27 P/Share
|
|
Mar 10
2022
|
Chad Patterson EVP Global Marketing |
SELL
Open market or private sale
|
Direct |
776
-4.85%
|
$311,176
$401.27 P/Share
|
|
Mar 09
2022
|
Donald Abbey EVP Global Business Services I |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,429
-2.18%
|
$1,392,174
$406.06 P/Share
|
|
Mar 09
2022
|
Andrew K Balo EVP Regulatory Strategy Clinic |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,430
-6.39%
|
$1,392,580
$406.06 P/Share
|
|
Mar 09
2022
|
Matthew Vincent Dolan EVP Strategy and Corporate Dev |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,615
-4.11%
|
$655,690
$406.06 P/Share
|
|
Mar 09
2022
|
Paul R Flynn EVP Global Revenue |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,967
-5.45%
|
$1,204,602
$406.06 P/Share
|
|
Mar 09
2022
|
Jacob Steven Leach EVP, Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,273
-1.83%
|
$1,734,838
$406.06 P/Share
|
|
Mar 09
2022
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,429
-2.99%
|
$1,392,174
$406.06 P/Share
|
|
Mar 09
2022
|
Chad Patterson EVP Global Marketing |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,821
-2.64%
|
$739,326
$406.06 P/Share
|
|
Mar 09
2022
|
Barry J. Regan EVP Operations |
SELL
Sale (or disposition) back to the issuer
|
Direct |
661
-3.65%
|
$268,366
$406.06 P/Share
|
|
Mar 09
2022
|
Kevin R Sayer President CEO and Chairman |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,985
-3.09%
|
$4,053,910
$406.06 P/Share
|
|
Mar 09
2022
|
Shelly Ramasamy Selvaraj SVP Chief Information Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,865
-4.13%
|
$757,190
$406.06 P/Share
|
|
Mar 09
2022
|
Sumi Shrishrimal SVP Chief Risk Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,357
-2.32%
|
$550,942
$406.06 P/Share
|
|
Mar 09
2022
|
Sadie Stern EVP, Chief HR Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
701
-3.74%
|
$284,606
$406.06 P/Share
|
|
Mar 09
2022
|
Jereme M Sylvain EVP, Chief Financal Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,951
-2.53%
|
$792,106
$406.06 P/Share
|
|
Mar 08
2022
|
Donald Abbey EVP Global Business Services I |
BUY
Grant, award, or other acquisition
|
Direct |
4,984
+8.5%
|
-
|
|
Mar 08
2022
|
Andrew K Balo EVP Regulatory Strategy Clinic |
BUY
Grant, award, or other acquisition
|
Direct |
4,984
+20.74%
|
-
|
|
Mar 08
2022
|
Michael Jon Brown EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,038
+50.0%
|
-
|
|
Mar 08
2022
|
Matthew Vincent Dolan EVP Strategy and Corporate Dev |
BUY
Grant, award, or other acquisition
|
Direct |
2,889
+21.68%
|
-
|
|
Mar 08
2022
|
Paul R Flynn EVP Global Revenue |
BUY
Grant, award, or other acquisition
|
Direct |
5,297
+21.67%
|
-
|
|
Mar 08
2022
|
Jacob Steven Leach EVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,741
+7.86%
|
-
|
|
Mar 08
2022
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
BUY
Grant, award, or other acquisition
|
Direct |
4,984
+11.24%
|
-
|
|
Mar 08
2022
|
Chad Patterson EVP Global Marketing |
BUY
Grant, award, or other acquisition
|
Direct |
5,297
+22.91%
|
-
|
|
Mar 08
2022
|
Barry J. Regan EVP Operations |
BUY
Grant, award, or other acquisition
|
Direct |
4,984
+21.58%
|
-
|
|
Mar 08
2022
|
Kevin R Sayer President CEO and Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
16,251
+12.78%
|
-
|
|
Mar 08
2022
|
Shelly Ramasamy Selvaraj SVP Chief Information Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,889
+15.55%
|
-
|
|
Mar 08
2022
|
Sumi Shrishrimal SVP Chief Risk Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,889
+16.02%
|
-
|
|
Mar 08
2022
|
Sadie Stern EVP, Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,297
+22.02%
|
-
|
|
Mar 08
2022
|
Jereme M Sylvain EVP, Chief Financal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,297
+20.97%
|
-
|
|
Mar 04
2022
|
Jereme M Sylvain EVP, Chief Financal Officer |
SELL
Open market or private sale
|
Direct |
600
-3.93%
|
$253,200
$422.94 P/Share
|
|
Mar 01
2022
|
Chad Patterson EVP Global Marketing |
SELL
Open market or private sale
|
Direct |
46
-0.37%
|
$18,998
$413.97 P/Share
|
|
Feb 23
2022
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
250
-0.72%
|
$98,500
$394.33 P/Share
|
|
Feb 14
2022
|
Kevin R Sayer President CEO and Chairman |
SELL
Open market or private sale
|
Direct |
3,000
-3.07%
|
$1,254,000
$418.04 P/Share
|
|
Feb 10
2022
|
Barbara Kahn Director |
SELL
Open market or private sale
|
Indirect |
4,666
-5.96%
|
$2,062,372
$442.28 P/Share
|
|
Jan 24
2022
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
250
-0.72%
|
$104,000
$416.77 P/Share
|
|
Jan 18
2022
|
Kevin R Sayer President CEO and Chairman |
SELL
Open market or private sale
|
Direct |
22,674
-10.22%
|
$9,885,864
$436.93 P/Share
|
|
Jan 18
2022
|
Kevin R Sayer President CEO and Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
38,586
+24.75%
|
-
|